Vázquez RJG, Juárez MA, García SVM, Solórzano SF

Language: Spanish
References: 35
Page: 123-130
PDF size: 318.26 Kb.

ABSTRACT

Introduction. 2.1% of HIV-1 infected population in Mexico corresponds to the group under 15 years old. Since 1995, highly effective antiretroviral therapy (HAART) was included for its treatment. Lipodystrophy syndrome is one of the therapy associated complication.
Objective. To describe frequency of lipodystrophy secondary to haart therapy in children infected with HIV.
Material and method. Descriptive, cross-sectional survey in a cohort. HIV-1 infected children, between six years old and under 17 years, who were receiving HAART therapy, were selected. From 56 patients, only 49 met inclusion criteria. Measurements of weight, height, triceps fold, waist circumference, leg and arm were made, and were percentile according to age and sex. Serum levels of triglycerides, cholesterol and glucose were measured. The total body fat, visceral fat and muscle mass were determined by means of the impedance scale.
Results. A frequency of 22.4% (N 11) of patients with lipodystrophy syndrome was found, distributed as follows: lipohypertrophy in seven patients (14.2%), lipoatrophy in three (6.1%) and one patient (2%) with mixed pattern. Regarding body fat, patients without SDL had 23%, SDL lipohypertrophy 29%, SDL lipoatrophy 11% and SDL mixed 25%. Patients without SDL had 5% visceral fat, SDL lipohypertrophy 16%, SDL lipoatrophy with 1% and SDL mixed with 26%. Among the metabolic alterations, the most common was hypertriglyceridemia, which was found in 36 (73.5%) patients, hypercholesterolemia in five (10.2%) and three (6.1%) patients with abnormal glucose values.
Conclusions. The frequency of lipodystrophy syndrome was higher than that reported in previous Mexican literature and lower than that reported in the world literature. The most frequent pattern was SDL with lipohypertrophy. The median total and visceral body fat was higher in children with SDL pattern lipohypertrophy and mixed.

REFERENCES

1. Robles-González, L.I., Beas-Ibarra, A., Cano-Saldaña, Y.M. y Martínez-Saucedo, M.G., “Estado nutricional de pacientes vih positivos”, Revista Médica md, 2011, 3 (2): 92-98.

2. López, L., Bautista, M., Pinzón, A. et al., “Alteraciones del crecimiento y en el estado nutricional de pacientes pediátricos infectados con vih”, Acta Pediátrica de México, 2014, 35 (4): 267-279.

3. Vigilancia epidemiológica de casos de vih/sida en México. Registro Nacional de Casos de sida, disponible en: https://www.gob.mx/censida/documentos/epidemiologia- registro-nacional-de-casos-de-sida. (Fecha de consulta: 12 de junio de 2018).

4. Vázquez Rosales, J.G., Solórzano Santos, F., Álvarez Muñoz, M.T., Sánchez Huerta, G. y Miranda Novales, M.G., “Infección por virus de inmunodeficiencia humana tipo 1 (vih-1) en pacientes pediátricos de México”, Rev Invest Clín, 2004, 56 (2): 153-168.

5. Fernández, A., Gutiérrez, R., Castro, M. et al., “Síndrome de lipodistrofia en pacientes con vih/sida que reciben terapia antirretroviral de gran actividad en Tepic, México”, Revista Cubana de Farmacia, 2012, 46 (2): 202-212.

6. Aurpibul, L., Puthanakit, T., Lee, B. et al., “Lipodistrophy and metabolic changes in hiv-infected children on nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy”, International Medical Press, 2007, 12: 1247-1254.

7. Colvin, C.J., “hiv/aids, chronic diseases and globalisation”, Global Health, 2011, 7 (1): 31-33.

8. Patel, K., Hernan, M., Williams, P., Seeger, J. et al., “Longterm effects og highly active antiretroviral therapy on cd4+ cell evolution among children and adolescents infected with hiv: 5 years and counting”, Clinic Infection Disease, 2008, 46 (11): 1751-1760.

9. López, P., Caicedo, Y., Rubiano, L. et al., “Alteraciones metabólicas con terapia antirretroviral altamente efectiva en niños positivos para vih, Cali, Colombia”, Infection, 2009, 13 (4): 283-292.

10. Coovadia, A., Abrams, E.J., Stehlau, R. et al., “Reuse of nevirapine in exposed hiv-infected children after protease inhibitor-based viral suppression: a randomized controlled trial”, Journal ama, 2010, 304: 1082-1090.

11. Aldrovandi, G., Lindsey, J.C., Jacobson, D.L. et al., “Morphologic and metabolic abnormalities in vertically hiv infected children and youth”, Acquired Inmune Deficiency Syndrome Journal, 2009, 23 (6): 661-672.

12. Ross, A.C. y McComsey, G.A., “Cardiovascular disease risk in pediatric hiv: the need for population-specific guidelines”, Acquired Inmune Deficiency Syndrome Journal, 2011, 57: 351-354.

13. Chantry, C.J., Hughes, M.D., Alvero, C. et al., “Lipid and glucose alterations in hiv-infected children beginning or changing antiretroviral therapy”, Pediatrics, 2008, 122: e129-e138.

14. Rhoads, M.P., Lanigan, J., Smith, C.J. et al., “Effect of specific art drugs on lipid changes and the need for lipid management in children with hiv”, Acquired Inmune Deficiency Syndrome Journal, 2011, 57 (5): 404-411.

15. Jacobson, D.L., Williams, P., Tassiopoulos, K. et al., “Clinical management and follow-up of hypercholesterolemia among perinatally hiv-infected children enrolled in the pactg 219c study”, Acquired Inmune Deficiency Syndrome Journal, 2011, 57: 413-420.

16. Shenoy, A., Ramapuram, J.T., Unnikrishan, B. et al., “Effect of lipodistrophy on the quality of life amon people living with hiv/aids (plhiv) on highly active antiretroviral therapy”, Journal of the International Association of Providers of aids Care, 2014, 13 (5): 471-475.

17. Kalyanasundaram, A.P., Jacob, S.M., Hemalatha, R. y Sivakumar, M.R., “Prevalence of lipodystrophy and dyslipidemia among patients with hiv infection on generic art in rural South India”, Journal International Association Physicians aids Care, 2012, 11 (5): 329-334.

18. Rajagopalan, R., Laitinen, D. y Dietz, B., “Impact of lipoatrophy on quality of life in hiv patients receiving antiretroviral therapy”, Acquired Inmune Deficiency Syndrome Journal Care, 2008, 20 (10): 1197-1201.

19. Saccardo, R.O., Suano, F.I., Beraldo, T.R. et al., “Lipodistrophy in children and adolescents with acquired immunodeficiency syndrome and its relationship with antiretroviral theraphy employed”, Journal of Pediatrics, 2009, 85 (4): 329-334.

20. Werner, M.L., Fonseca, V.M., Pone, M.V. et al., “Lipodystrophy syndrome and cardiovascular risk factors in children and adolescents infected with hiv/aids receiving highly active antiretroviral therapy”, Journal of Pediatrics, 2010, 86 (1): 27-32.

21. Muñoz, M., Santos, J.I. y Pavía, N., “Redistribución de grasa y alteraciones metabólicas en niños y adolescentes infectados por vih/sida con tratamiento antirretroviral altamente activo”, Boletín Médico del Hospital Infantil de México, 2009, 66: 343-349.

22. Solórzano Santos, F., Gochicoa Rangel, L.G., Palacios Saucedo, G., Vázquez Rosales, G. y Miranda Novales, M.G., “Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors”, Arch Med Res, 2006, 37 (1): 129-132.

23. McComsey, G., Paulsen, D., Lonergan, T., Milano, D., Williams, V., Pakes, G. et al., “Improvements in body fat, mitochondrial dna (mtdna) levels and adipocyte apoptosis 48 weeks after replacing of stavudine (d4t) with abacavir (abc) or zidovudine (zdv) appear independent of cellular cytokine mrna levels”, Infectious Diseases Society of America, 2003, 16: 250-260.

24. Lichtenstein, K.A., Ward, D.J., Moorman, A.C., Delaney, K.M., Young, B., Palella, F.J., Jr., et al., Clinical assessment of hiv-associated lipodystrophy in an ambulatory population”, Journal Acquired Inmune Deficiency Syndrome, 2001, 15: 1389-1398.

25. McComsey, G.A. y Morrow, J.D., “Lipid oxidative markers are significantly increased in lipoatrophy, but not in sustained asymptomatic hyperlactatemia”, Journal Acquired Inmune Deficiency Syndrome, 2003, 34 (1): 45-49.

26. Walker, U.A., Venhoff, N., Koch, E.C. et al., “Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells”, International Medical Press Antiviral Therapy, 2003, 8: 463-470.

27. Strehlau, R., Coovadia, A., Abrams, E.J. et al., “Lipid profiles in young hiv-infected children initiating and changing antiretroviral therapy”, Journal Acquired Inmune Deficiency Syndrome, 2012, 60 (4): 369-376.

28. Badillo, K., Prieto, L., Toledano, M. et al., “Características de niños con infección por virus de la inmunodeficiencia humana-1 que reciben tratamiento antirretroviral de gran actividad: estudio de corte transversal”, Anales de Pediatría, 2012, 76 (6): 317-323.

29. Sterne, J.A., May, M., Costagliola, D. et al., “Timming of initiation of antiretroviral therapy in aids-free hiv-1-infected patients: a collaborative analysis of 18 hiv cohort studies”, Lancet, 2009, 373 (9672): 1352-1363.

30. Sztam, K.A., Jiang, H., Jurgrau, A., Deckelbaum, R.J. y Foca, M.D., “Early increases in concentrations of total, ldl, and hdl cholesterol in hiv-infected children following new exposure to antiretroviral therapy”, Journal Pediatric Gastroenterology Nutrition, 2011, 52: 495-498.

31. Brewinski, M., Megazzini, K., Freimanis, L. et al., “Dyslipidemia in a cohort of hiv-infected Latin American children receiving highly active antiretroviral therapy”, Journal of Tropical Pediatrics, 2011, 57 (5): 324-332.

32. Ene, L., Goetghebuer, T., Hainaut, M. et al., “Prevalence of lipodystrophy in hiv-infected children: a cross sectional study”, European Journal of Pediatrics, 2007, 1666: 13-21.

33. Angulo, D. y Castillo, M.E., “Prevalencia de dislipidemia y lipodistrofia en niños con infección vih y tratamiento antirretroviral. Instituto Nacional de Salud del Niño, 2007”, Revista Peruana de Pediatría, 2010, 63 (1): 1-10.

34. Castro, P., Martínez, M.Y., González, I., Velásquez, J., Castillo, G. y Sánchez, L., “Evaluación neuropsicológica, factores psicosociales y comorbilidad psiquiátrica en pacientes pediátricos infectados con el vih”, Revista Chilena de Infectología, 2011, 28: 248-254.

35. Asociación Americana de Diabetes, “Clasificación y diagnóstico de la diabetes mellitus, 2014, disponible en: http://www.diabetes.org/es/.